神经氨酸酶抑制剂类抗流感病毒药物的研究进展  

Research Progress in Neuraminidase Inhibitor Type Anti-influenza Drugs

作　　者：元科阳 廖洪梅[1] 李东林[1] YUAN Ke-yang;LIAO Hong-mei;LI Dong-lin(Department of Biochemical Engineering,Fuyang Institute of Technology,Fuyang Anhui 236031,China)

机构地区：[1]阜阳职业技术学院生化工程系,安徽阜阳236031

出　　处：《抗感染药学》2022年第7期938-942,共5页Anti-infection Pharmacy

基　　金：安徽高校自然科学研究项目(编号:KJ2021A1347,KJ2021A1348)

摘　　要：神经氨酸酶(neuraminidase,NA)是抗流感病毒药物的重要作用靶点之一,已上市的神经氨酸酶抑制剂(neuraminidase inhibitors,NAIs)均为唾液酸衍生物,其活性较好,但缺点是结构中手性中心多、合成较复杂。病毒的变异促使着人类开发新的抗流感病毒药。近年来,许多的非唾液酸类NAIs被发现,其发现或基于药效团或偶然发现,或基于天然产物开发,或基于虚拟筛选。此外,分子印迹、网络药理学等新技术的应用,也促进了新型NAIs类抗流感病毒药物的研发。该文对新近发现的非唾液酸类新型NAIs及其开发技术进行了综述,并对相关研究进行了分析。Neuraminidase(NA)is one of important targets of anti-influenza drugs.The marketed neuraminidase inhibitors(NAIs)are all sialic acid derivatives with good activity,but have the disadvantages of many chiral centers in the structure and complicated synthesis.Virus mutations prompt people to develop new anti-influenza drugs.In recent years,many non-sialic acid NAIs have been discovered,either on the basis of pharmacophore or serendipitous discovery,or natural product development or virtual screening.In addition,the application of new technologies such as molecular blotting and network pharmacology has facilitated the research and development of new NAIs type anti-influenza drugs.This paper summarizes newly discovered non-sialic acid new NAIs and their development technologies,and analyzes related studies.

关 键 词：神经氨酸酶抑制剂 抗流感病毒药物 研究进展 

分 类 号：R978.7[医药卫生—药品]